AERI
NASDAQAerie Pharmaceuticals Inc.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
- SECSEC Form 15-12G filed by Aerie Pharmaceuticals Inc.15-12G - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- NEWSAerie Pharmaceuticals's Return On Capital Employed OverviewAerie Pharmaceuticals (NASDAQ:AERI) brought in sales totaling $36.13 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 38.49%, resulting in a loss of $26.83 million. In Q2, Aerie Pharmaceuticals brought in $33.31 million in sales but lost $19.37 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Aerie P
- PRAlcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical BusinessLeveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi
- INSIDERSEC Form 4: Mchugh Julie returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Mcgraw Benjamin F Iii returned $640,256 worth of shares to the company (41,984 units at $15.25), closing all direct ownership in the company to satisfy tax liability4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Mcdonnell Peter J returned $121,924 worth of shares to the company (7,995 units at $15.25), closing all direct ownership in the company (for withholding tax)4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Kopczynski Casey C. returned $4,273,721 worth of shares to the company (280,244 units at $15.25), closing all direct ownership in the company (withholding tax)4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Lang Peter Frederick returned $706,029 worth of shares to the company (46,297 units at $15.25), closing all direct ownership in the company (for withholding tax)4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Larocca John returned $817,171 worth of shares to the company (53,585 units at $15.25), closing all direct ownership in the company to satisfy tax liability4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Gryska David W returned $205,738 worth of shares to the company (13,491 units at $15.25), closing all direct ownership in the company (tax liability)4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Du Toit Michael returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Croarkin Richard returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company (for withholding tax)4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Calabrese Jeffrey returned $283,421 worth of shares to the company (18,585 units at $15.25), closing all direct ownership in the company (tax withholding)4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- INSIDERSEC Form 4: Kannan Raj returned $3,290,691 worth of shares to the company (215,783 units at $15.25), closing all direct ownership in the company to cover taxes4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECSEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECAerie Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits8-K - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
- SECAerie Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
AERI FAQ
7 questionsWhat does Aerie Pharmaceuticals Inc. do?
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and...Where does AERI stock trade?
Aerie Pharmaceuticals Inc. (AERI) is listed on NASDAQ.What sector and industry is AERI in?
Aerie Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Aerie Pharmaceuticals Inc. go public?
Aerie Pharmaceuticals Inc. (AERI) completed its IPO in 2013.What are analysts saying about AERI?
Aerie Pharmaceuticals Inc. has had 6 recent analyst actions on file. The most recent action was from Citigroup: Neutral with a $1525.00 price target on 2022-08-29. Recent price targets range from $1400.00 to $2400.00.What companies are similar to AERI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AERI side-by-side with any of them on Quantisnow.How can I track AERI on Quantisnow?
Quantisnow aggregates Aerie Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AERI to receive live email and push alerts on every new disclosure.